TFCP2 and sarcoma: Our data indicate that FUS/EWSR1-TFCP2-positive sarcoma is a distinct disease entity that does not fit the pattern of genetically silent fusion-driven sarcomas and provide insight into potential therapeutic vulnerabilities that may inform clinical decision-making in this difficult-to-treat sarcoma subtype.